Eli Lilly rises after China approves oral weight-loss pill orforglipron
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Eli Lilly and Co (NYSE:LLY) shares rose 0.35% to $1,442.39 at 9:40 a.m. ET in early regular-session trading on November 12 after China's medicines regulator approved orforglipron, Lilly's oral weight-loss treatment. The shares had traded…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe approval opens one of the largest obesity markets to Lilly's oral pill, where it will compete with Novo Nordisk and Pfizer.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01China's medicines regulator approved orforglipron, Lilly's oral weight-loss treatment.
- 02LLY shares rose 0.35% to $1,442.39 in early regular-session trading on November 12.
- 03Lilly had already committed $3 billion to expand manufacturing in China for oral GLP-1 supply.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Eli Lilly and Company1,430.74 USDMarket closedtoday -0.46%Positive Novo Nordisk A/S40.65 USDMarket closedtoday -1.07%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets